The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults with type 2 diabetes, developer Novo Nordisk announced. Of note, the agency ...

A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

Advocates expect the young adult population to especially benefit from the bill, since many struggle to get high-quality ...

Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.

Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t ...

A monthly out-of-pocket cap on insulin for Medicare beneficiaries with type 2 diabetes is linked to some clinical benefits as ...

Read more from STAT contributor Brianna Abbott on the popular vote winner. And STAT’s Amanda Erickson, who edits this very newsletter, has a dispatch on the research our editors chose as the best ...

*A gene therapy that may eliminate, or significantly reduce, the need for daily insulin injections is preparing to enter ...

Insulin resistance occurs when your body’s cells become less responsive to insulin, the hormone responsible for moving s ...

The prices of seven essential medicines, including insulin, have been significantly increased, triggering fresh concerns among patients and healthcare providers in Khyber-Pakhtunkhwa.The most alarming ...

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal insulin, Novo Nordisk announced. Insulin icodec-abae (Awiqli, Novo Nordisk) ...